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Abstract
Background: High oral bioavailability of antimicrobial agents can result in the replacement of intravenous (IV)
therapy with oral therapy when a patient meets defined clinical criteria. However, few studies have evaluated
the effects of switching antibiotic administration route in Japan, especially for linezolid. This study evaluated an
IV-to-oral antibiotic switching program for linezolid treatment at a university hospital in Japan.
Methods: In a retrospective cohort study of 73 patients, we assessed the efficacy and safety of IV-to-oral linezolid
therapy (n = 21 patients) compared with IV therapy alone (n = 52 patients).
Results: Duration of linezolid treatment, changes in C-reactive protein or platelet count from baseline,
re-administration of anti-methicillin-resistant Staphylococcus aureus agent within 90 days of discharge, and
mortality within 28 days of discharge were not significantly different between the two groups.
Conclusions: An IV-to-oral switching program could reduce the duration of IV linezolid therapy without
worsening clinical outcomes in Japanese patients receiving linezolid therapy.
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Background
Appropriate use of antimicrobial agents is important for
clinical outcomes, patient safety, and minimizing drug re-
sistance [1–3]. Stewardship programs promote judicious
use of antimicrobial agents by selecting the appropriate
drug, dose, duration, and route of administration [4].
The high oral bioavailability of antimicrobial agents
such as fluoroquinolones, linezolid, fluconazole, and vor-
iconazole justifies the conversion of intravenous (IV)
therapy to oral therapy if a patient meets defined clinical
criteria. IV-to-oral switching programs for antibiotics
were implemented in several countries in the 1990s.
This strategy can result in lower costs as well as reduced
burden for nursing staff, prevalence of catheter-related
infections, and duration of hospital stay [5, 6]. Few stud-
ies to date have evaluated the effects of switching admin-
istration routes for antibiotic therapy in Japan from IV
to oral, especially for linezolid, which is why the present
study was carried out. This study evaluated an IV-to-oral
antibiotic switching program for linezolid treatment at a
university hospital in Japan.
Methods
Design and study population
We conducted a retrospective cohort study of patients
hospitalized at Ehime University Hospital (Ehime,
Japan). The study was carried out in accordance with the
guidelines for human studies adopted by the Ethics
Committee of Ehime University Hospital (approval num-
ber: 1408002). Data were collected from records dating
from 1 May 2009 to 30 April 2014.
We excluded patients who had received antibiotic
therapy for <5 days, had neutropenic disease, or were
aged <15 years. We divided patients into two groups,
IV to oral therapy (IOT) and IV therapy alone (IVT).
Criteria to define inappropriate IV administration of
antibiotics were used in switching patients from IV to
oral route. The criteria included: body temperature of
38 °C during the previous 24 h; decreased or normal
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blood leucocyte count; absence of unexplained tachy-
cardia; functional gastrointestinal tract (patient could
eat or had a functional gastric feeding tube); and ab-
sence of vomiting, diarrhea, or severe sepsis [7]. In
each case, pharmacists from the infection control
team had recommended the switching from an IV
route to an oral route. Assignment of patients to ei-
ther group was determined by the attending phys-
ician, who also made the decision on whether to
discontinue linezolid therapy.
Outcome measures
Several indicators were used to assess the efficacy and
safety of switching from IV to oral linezolid therapy in
comparison with IV therapy alone: decrease in C-reactive
protein (CRP) level of ≥30 % from baseline; decrease in
platelet count of ≥30 % from baseline; re-administration
of an anti-methicillin-resistant Staphylococcus aureus
(MRSA) agent <90 days after hospital discharge; and death
<28 days after hospital discharge [8–10].
Statistical analysis
Statistical analysis was performed using add-in software
for Mac Statistical Analysis v2.0 (Esumi, Tokyo, Japan).
To compare differences in the distribution of baseline
characteristics, we used the x2 test for binary data and
Student’s t-test. The chi-squared test was used for
discrete variables. Values of p < 0.05 were considered
significant.
Results
Seventy-three patients were evaluated retrospectively.
Baseline characteristics of the IOT group (21 patients)
and IVT group (52 patients) are shown in Table 1. Age,
sex, white blood cell count, CRP, and platelet count were
similar between the groups.
Table 2 shows the clinical outcomes of the two groups.
Duration of linezolid treatment, reduction in CRP level
of ≥30 % from baseline, reduction in platelet count of
≥30 % from baseline, re-administration of an anti-MRSA
agent <90 days after hospital discharge, and death
<28 days after hospital discharge were not significantly
different between the two groups.
Switching from IV to oral linezolid therapy was associ-
ated with a reduction in drug costs (\2,540,820
[US$21,173]; average \9,964 [US$83]/day/person), as IV
formulations (average \36,574 [$305]/day/person) were
more expensive (p < 0.001) than oral formulations (aver-
age \26,610 [$222]/day/person).
Discussion
Reductions in CRP level and platelet count of ≥30 %
from baseline were not significantly different between
the IOT and IVT groups. Additionally, there was no
significant difference in duration of linezolid treatment,
re-administration of an anti-MRSA agent <90 days after
hospital discharge, or death <28 days after hospital dis-
charge between the two groups. These results suggest
that switching from IV to oral linezolid therapy might
be as effective and safe as maintaining patients on IV
linezolid therapy alone.
A meta-analysis showed that earlier switching to
antibiotic administration via the oral route was as ef-
fective as continuing IV therapy in patients with
community-acquired pneumonia [11]. Similar results
have been observed for intra-abdominal infections
and spontaneous bacterial peritonitis [12, 13]. In
Japan, earlier switching to antibiotic administration
via the oral route has been shown to result in earlier
clinical stability and reduced use of unnecessary anti-
biotics, without worsening clinical outcomes in
patients hospitalized with mild and moderate
community-acquired pneumonia [14]. However, re-
ports on various MRSA infections acquired while re-
ceiving linezolid therapy are scarce. We therefore
evaluated Japanese patients with various MRSA infec-
tions receiving linezolid therapy.
In the present study, the decision to implement IV
therapy and to switch from IV to oral therapy was at
the discretion of the attending physician. Incidence of
switching from IV to oral linezolid therapy was low
(21/73, 28.8 %), likely as a result of attending physi-
cians’ attitudes towards switching administration route
in Japan [14].
Table 1 Statistical analysis of patient characteristics in the








Age (years) 64 ± 19 65 ± 16 0.69
Male (n [%]) 19 (90.5) 40 (76.9) 0.18
White blood cell count 8.8 ± 3.8 10.6 ± 5.7 0.20
CRP 6.9 ± 4.8 8.6 ± 6.7 0.20




7 (33.3) 13 (25.0) 0.47
Skin, soft tissue, bone
or joint infection
7 (33.3) 20 (38.5) 0.68
Urinary/genital tract
infection
2 (9.5) 3 (5.8) 0.57
Intra-abdominal
infection
1 (4.8) 2 (3.8) 0.86
Other/unknown 4 (19.0) 14 (26.9) 0.48
CRP C-reactive protein; data are the mean ± standard deviation
P-values were calculated based on Students t-test or Welch’s t-test for
continuous variables and chi-squared analysis for discrete variables
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The direct cost saving of switching from IV to oral
linezolid therapy was \9964 ($83)/day/person. Indirect
costs of IV preparation and administration have been es-
timated to add 13 %–113 % to the costs of drugs [15].
The direct cost saving of switching from IV to oral linez-
olid therapy was significant. Therefore, we recommend
switching from IV to oral linezolid therapy where
applicable.
Our study had some limitations. First, it was not
randomized in design, and data were collected retro-
spectively at a single institution. Second, a small sam-
ple size was included. Furthermore, a selection bias
may have been present because it was the attending
physician who decided whether to switch the adminis-
tration route. Finally, we did not evaluate the length
of hospital stay.
Conclusions
Switching from IV to oral linezolid therapy could reduce
the duration of IV linezolid therapy without worsening
clinical outcomes of Japanese patients. The direct cost
saving of switching from IV to oral linezolid therapy was
significant. However, our study was limited by its small
sample size.
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